



**JUNE 12, 2019**  
**#NASHDAY**



Join us to raise awareness about Non-alcoholic  
Steatohepatitis & Fatty Liver Disease

**The Global Liver Institute (GLI) and GLI NASH Council  
In collaboration with Senator Bill Cassidy (LA)**

Invite you to an International NASH Day (IND) Educational Briefing on  
**The Rising Risks of Nonalcoholic Fatty Liver Disease (NAFLD) and  
Nonalcoholic Steatohepatitis (NASH)**

**June 12, 2019**

**Senate Russell Office Building 188**

**12:00PM - 1:00PM**

Light Lunch will be provided

**Moderator:**

- **Donna Cryer, JD**, President & CEO, Patient Advocate, Global Liver Institute (GLI), Washington, DC

**Panelists:**

- **Dr. Rita Basu, MD**, Professor, Division of Endocrinology, Department of Medicine, University of Virginia, Endocrine Society, Charlottesville, Virginia
- **Dr. Nadege T. Gunn, MD**, Physician Investigator, Gastroenterology/Hepatology, Pinnacle Clinical Research, Austin, Texas
- **Kimberly Martinez**, NASH Patient Advocate, GLI Advanced Advocacy Academy (A3), Broken Arrow, Oklahoma
- **Dr. Zobair M. Younossi, MD, MPH, FAGG, AGAF, FAASLD**, Chairman, Department of Medicine, Inova Fairfax Medical Campus, Professor of Medicine, Inova Fairfax Hospital, American Gastroenterological Association, Fairfax, Virginia

Obesity, diabetes, metabolic syndrome, chronic kidney disease and cardiovascular disease (CVD) are all impacted by and interconnected with two chronic liver diseases, Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH).

NAFLD is the leading cause of chronic liver disease, and affects almost 1 in 4 people worldwide. Of those with NAFLD, approximately 20% develop its more severe form known as NASH. According to NIH, up to 12% of adults in the U.S. currently have NASH and are at risk for liver cancer and/or liver transplant.

Although NASH was discovered almost 40 years ago, the prevalence has doubled in the last 15 years, and challenges remain to optimise disease diagnosis and management.

**Please join us for an educational briefing that will provide an overview of NASH from our nation's leading clinicians and liver patient advocates.**

**Learn about the ways in which NASH impacts the liver, why there is a need to reduce the significant variation in assessment and diagnosis of NASH, what treatment options are currently available for NASH, and what the rising prevalence of NASH means for our healthcare system going forward.**

*Please RSVP to Andrew Scott at [ascott@globalliver.org](mailto:ascott@globalliver.org).*

*The Global Liver Institute (GLI) is a patient-driven 501(c)(3) nonprofit organization committed to improving the lives of individuals and families impacted by liver disease by promoting innovation, encouraging collaboration, and scaling optimal approaches to help eradicate liver diseases.*